# The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

> **NCT03487913** · PHASE2 · COMPLETED · sponsor: **Palladio Biosciences** · enrollment: 31 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease

## Interventions

- **DRUG:** Lixivaptan

## Key facts

- **NCT ID:** NCT03487913
- **Lead sponsor:** Palladio Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-14
- **Primary completion:** 2019-12-02
- **Final completion:** 2020-02-11
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03487913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03487913, "The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03487913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*